newsfilter
← Latest News
Business Wire·

MyMD Pharmaceuticals Announces Positive Clinical Data in Advance of Upcoming Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan

Phase 1 dose-ranging study results meet primary endpoints Drug demonstrates statistically significant efficacy in reducing levels of the root cause of aging, TNF-α, in the blood Data from fully funded Phase 2 trial anticipated in first half o